Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $8.00

Sana Biotechnology, Inc. (NASDAQ:SANA) has earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $8.00.

Several brokerages have recently issued reports on SANA. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. HC Wainwright lowered their price objective on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a report on Monday, December 29th. Morgan Stanley reissued an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a research note on Friday, March 13th. Finally, Bank of America raised their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $3.03 on Tuesday. The firm has a 50 day simple moving average of $3.91 and a 200 day simple moving average of $4.13. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $6.55. The firm has a market cap of $808.62 million, a P/E ratio of -3.12 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). On average, sell-side analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Marex Group plc bought a new stake in Sana Biotechnology in the second quarter valued at about $10,423,000. Balyasny Asset Management L.P. bought a new position in Sana Biotechnology during the fourth quarter worth about $6,834,000. Vanguard Group Inc. grew its position in shares of Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after buying an additional 1,517,474 shares during the period. JPMorgan Chase & Co. grew its position in shares of Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after buying an additional 1,375,029 shares during the period. Finally, State Street Corp increased its stake in shares of Sana Biotechnology by 20.6% in the 4th quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after acquiring an additional 1,374,300 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.